"Leucovorin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The active metabolite of FOLIC ACID. Leucovorin is used principally as an antidote to FOLIC ACID ANTAGONISTS.
| Descriptor ID |
D002955
|
| MeSH Number(s) |
D03.633.100.733.631.400.800.350.450 D08.211.840.300.500
|
| Concept/Terms |
Leucovorin- Leucovorin
- Folinic Acid-SF
- Folinic Acid SF
- Leukovorin
- Leukovorum
- Folinic Acid
- Acid, Folinic
Citrovorum Factor- Citrovorum Factor
- Factor, Citrovorum
- Calcium Leucovorin
- Leucovorin, Calcium
- Calcium Folinate
- Folinate, Calcium
N(5)-Formyltetrahydrofolate- N(5)-Formyltetrahydrofolate
- 5-Formyltetrahydropteroylglutamate
- 5 Formyltetrahydropteroylglutamate
- 5-Formyltetrahydrofolate
- 5 Formyltetrahydrofolate
|
Below are MeSH descriptors whose meaning is more general than "Leucovorin".
Below are MeSH descriptors whose meaning is more specific than "Leucovorin".
This graph shows the total number of publications written about "Leucovorin" by people in this website by year, and whether "Leucovorin" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 1 | 2 | 3 |
| 1995 | 0 | 3 | 3 |
| 1996 | 0 | 3 | 3 |
| 1997 | 1 | 2 | 3 |
| 1998 | 0 | 4 | 4 |
| 1999 | 1 | 2 | 3 |
| 2000 | 0 | 1 | 1 |
| 2001 | 0 | 3 | 3 |
| 2002 | 1 | 4 | 5 |
| 2003 | 0 | 2 | 2 |
| 2004 | 0 | 3 | 3 |
| 2005 | 1 | 1 | 2 |
| 2006 | 0 | 2 | 2 |
| 2007 | 0 | 3 | 3 |
| 2008 | 0 | 2 | 2 |
| 2010 | 0 | 3 | 3 |
| 2011 | 0 | 2 | 2 |
| 2012 | 0 | 3 | 3 |
| 2013 | 0 | 3 | 3 |
| 2014 | 0 | 3 | 3 |
| 2015 | 1 | 2 | 3 |
| 2016 | 0 | 3 | 3 |
| 2017 | 0 | 4 | 4 |
| 2018 | 0 | 2 | 2 |
| 2019 | 0 | 2 | 2 |
| 2020 | 0 | 3 | 3 |
| 2021 | 0 | 1 | 1 |
| 2022 | 0 | 2 | 2 |
| 2023 | 0 | 1 | 1 |
| 2024 | 0 | 3 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Leucovorin" by people in Profiles.
-
Alliance A022104/NRG-GI010: The Janus Rectal Cancer Trial: a randomized phase II/III trial testing the efficacy of triplet versus doublet chemotherapy regarding clinical complete response and disease-free survival in patients with locally advanced rectal cancer. BMC Cancer. 2024 Jul 26; 24(1):901.
-
Pembrolizumab Plus Binimetinib With or Without Chemotherapy for MSS/pMMR Metastatic Colorectal Cancer: Outcomes From KEYNOTE-651 Cohorts A, C, and E. Clin Colorectal Cancer. 2024 Jun; 23(2):183-193.
-
Radiation Therapy Quality Assurance Analysis of Alliance A021501: Preoperative mFOLFIRINOX or mFOLFIRINOX Plus Hypofractionated Radiation Therapy for Borderline Resectable Adenocarcinoma of the Pancreas. Int J Radiat Oncol Biol Phys. 2024 Sep 01; 120(1):111-119.
-
Preoperative Treatment of Locally Advanced Rectal Cancer. N Engl J Med. 2023 Jul 27; 389(4):322-334.
-
Efficacy and safety of dilpacimab (ABT-165) versus bevacizumab plus FOLFIRI in metastatic colorectal cancer: a phase II study. Future Oncol. 2022 Sep; 18(27):3011-3020.
-
A Systematic Review of Conversion to Resectability in Unresectable Metastatic Colorectal Cancer Chemotherapy Trials. Am J Clin Oncol. 2022 08 01; 45(8):366-372.
-
Age and comorbidity association with survival outcomes in metastatic colorectal cancer: CALGB 80405 analysis. J Geriatr Oncol. 2022 05; 13(4):469-479.
-
Pharmacogenetic study in gastric cancer patients treated with adjuvant fluorouracil/leucovorin or epirubicin/cisplatin/fluorouracil before and after chemoradiation on CALGB 80101 (Alliance). Pharmacogenet Genomics. 2021 12 01; 31(9):215-220.
-
Genomic Analysis of Germline Variation Associated with Survival of Patients with Colorectal Cancer Treated with Chemotherapy Plus Biologics in CALGB/SWOG 80405 (Alliance). Clin Cancer Res. 2021 01 01; 27(1):267-275.
-
5-FU, Irinotecan, Nab-Paclitaxel in Gastrointestinal Cancers-Response. Clin Cancer Res. 2020 07 15; 26(14):3890.